Tokyo Tape
Sign in
← Noile-Immune Biotech

Quarterly report · Q2

4893.TEDINET S100RP80
Period2023-01-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedNo
Data checks9 of 9 passed
Key figures · 28
MetricValuePeriodScopeSource row
Operating income−¥482m2023-01-01 → 2023-06-30StandaloneOperating income
Ordinary income−¥832m2023-01-01 → 2023-06-30StandaloneOrdinary income
Ordinary income−¥384m2022-01-01 → 2022-12-31StandaloneOrdinary income loss (5-year summary)
Profit before tax−¥832m2023-01-01 → 2023-06-30StandaloneIncome before income taxes
Net income−¥834m2023-01-01 → 2023-06-30StandaloneProfit loss
Net income−¥387m2022-01-01 → 2022-12-31StandaloneNet income loss (5-year summary)
Total assets¥6.1bnat 2023-06-30StandaloneAssets
Total assets¥4.6bnat 2022-12-31StandaloneAssets
Total liabilities¥199mat 2023-06-30StandaloneLiabilities
Total liabilities¥340mat 2022-12-31StandaloneLiabilities
Net assets / equity¥5.9bnat 2023-06-30StandaloneNet assets
Net assets / equity¥4.3bnat 2022-12-31StandaloneNet assets
Cash and deposits¥6.0bnat 2023-06-30StandaloneCash and deposits
Cash and deposits¥4.5bnat 2022-12-31StandaloneCash and deposits
Cash & equivalents¥6.0bnat 2023-06-30StandaloneCash and cash equivalents
Cash & equivalents¥4.5bnat 2022-12-31StandaloneCash and cash equivalents
Operating cash flow−¥509m2023-01-01 → 2023-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥107m2022-01-01 → 2022-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥5m2023-01-01 → 2023-06-30StandaloneNet cash provided by used in investment activities
Financing cash flow¥1.9bn2023-01-01 → 2023-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥488m2022-01-01 → 2022-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-21.032023-01-01 → 2023-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-8.542023-04-01 → 2023-06-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-9.872022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
Equity ratio96.6%at 2023-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio92.5%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Shares issued43,202,865at 2023-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued39,579,865at 2022-12-31StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 284
ItemContextValueUnit
Income taxesCurrentYTDDuration_NonConsolidatedMember1213000JPY
Profit lossCurrentYTDDuration_NonConsolidatedMember-833554000JPY
Income before income taxesCurrentYTDDuration_NonConsolidatedMember-832341000JPY
Interest income ope cfCurrentYTDDuration_NonConsolidatedMember-22000JPY
Listing expenses ope cfCurrentYTDDuration_NonConsolidatedMember341602000JPY
Stock issuance cost ope cfCurrentYTDDuration_NonConsolidatedMember8632000JPY
Foreign exchange losses gains ope cfCurrentYTDDuration_NonConsolidatedMember382000JPY
Decrease increase in inventories ope cfCurrentYTDDuration_NonConsolidatedMember-4243000JPY
Decrease increase in advance payments ope cfCurrentYTDDuration_NonConsolidatedMember-133000JPY
Decrease increase in consumption taxes refund receivable ope cfCurrentYTDDuration_NonConsolidatedMember-59227000JPY
Increase decrease in accounts payable other ope cfCurrentYTDDuration_NonConsolidatedMember24605000JPY
Increase decrease in accrued expenses ope cfCurrentYTDDuration_NonConsolidatedMember-519000JPY
Increase decrease in contract liabilities ope cfCurrentYTDDuration_NonConsolidatedMember4020000JPY
Other net ope cfCurrentYTDDuration_NonConsolidatedMember10460000JPY
Subtotal ope cfCurrentYTDDuration_NonConsolidatedMember-506784000JPY
Interest and dividends income received ope cf inv cfCurrentYTDDuration_NonConsolidatedMember18000JPY
Income taxes paid ope cfCurrentYTDDuration_NonConsolidatedMember-2420000JPY
Income taxes refund ope cfCurrentYTDDuration_NonConsolidatedMember6000JPY
Net cash provided by used in operating activitiesCurrentYTDDuration_NonConsolidatedMember-509179000JPY
Payments for guarantee deposits inv cfCurrentYTDDuration_NonConsolidatedMember-5316000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration_NonConsolidatedMember-5316000JPY
Proceeds from issuance of common stock fin cfCurrentYTDDuration_NonConsolidatedMember2457905000JPY
Payments of listing expenses fin cfCurrentYTDDuration_NonConsolidatedMember-510815000JPY
Net cash provided by used in financing activitiesCurrentYTDDuration_NonConsolidatedMember1947090000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration_NonConsolidatedMember1432595000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember4520997000JPY
Cash and cash equivalentsCurrentQuarterInstant_NonConsolidatedMember5953593000JPY
Directors compensations sgaCurrentYTDDuration_NonConsolidatedMember35072000JPY
Patent related expense sgaCurrentYTDDuration_NonConsolidatedMember18346000JPY
Payroll and allowances sgaCurrentYTDDuration_NonConsolidatedMember45665000JPY
Compensations sgaCurrentYTDDuration_NonConsolidatedMember19660000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-08-14
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第９期第２四半期（自2023年４月１日　至2023年６月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)ノイルイミューン・バイオテック株式会社
Company name in english cover pageFilingDateInstantNoile-Immune Biotech Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　玉田　耕治
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区芝大門二丁目12番10号
Telephone number address of registered headquarter cover pageFilingDateInstant03-5843-7819
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役管理部長　永井　寛子
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区芝大門二丁目12番10号
Telephone number nearest place of contact cover pageFilingDateInstant03-5843-7819
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役管理部長　永井　寛子
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE38453
Fund codeFilingDateInstant－
Security codeFilingDateInstant48930
Filer name in japaneseFilingDateInstant
Original text (Japanese)ノイルイミューン・バイオテック株式会社

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 9 of 9 passed
balance sheet identitynon_consolidated 2022-12-31pass rounding
balance sheet identitynon_consolidated 2023-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-06-30pass
statement vs summary · operating cash flownon_consolidated 2023-01-01/2023-06-30pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2023-06-30pass